Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2025)
Historic Current Deferred Revenue for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $14.2 million.
- Protagonist Therapeutics' Current Deferred Revenue fell 6077.35% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 6077.35%. This contributed to the annual value of $18.9 million for FY2024, which is 62960000.0% up from last year.
- Protagonist Therapeutics' Current Deferred Revenue amounted to $14.2 million in Q3 2025, which was down 6077.35% from $14.7 million recorded in Q2 2025.
- Protagonist Therapeutics' Current Deferred Revenue's 5-year high stood at $45.0 million during Q1 2024, with a 5-year trough of $3000.0 in Q3 2023.
- For the 5-year period, Protagonist Therapeutics' Current Deferred Revenue averaged around $12.5 million, with its median value being $4.0 million (2021).
- In the last 5 years, Protagonist Therapeutics' Current Deferred Revenue crashed by 9857.21% in 2022 and then soared by 120656666.67% in 2024.
- Protagonist Therapeutics' Current Deferred Revenue (Quarter) stood at $1.6 million in 2021, then crashed by 95.69% to $69000.0 in 2022, then plummeted by 95.65% to $3000.0 in 2023, then skyrocketed by 629600.0% to $18.9 million in 2024, then dropped by 24.83% to $14.2 million in 2025.
- Its Current Deferred Revenue was $14.2 million in Q3 2025, compared to $14.7 million in Q2 2025 and $16.9 million in Q1 2025.